|
 Nolasiban did not meet the primary endpoint of an increase in
ongoing pregnancy at 10 weeks, with 39.1% of women who got the
placebo experiencing an ongoing pregnancy, compared with 40.5% of
women who got nolasiban, the company said in a statement.
This proposed use of nolasiban, an oral oxytocin receptor antagonist
licensed from Merck KGaA to help women getting IVF therapy, had been
a central part of ObsEva's plans. The trial failure leaves the
company with drug candidates for endometriosis and potentially
dangerous pre-term labor.
"We are extremely disappointed with these unexpected results, not in
the least for the millions of women hoping to have a baby through
IVF," said Ernest Loumaye, a gynaecologist and former Serono drug
developer who founded ObsEva.
[to top of second column] |
"We have decided to discontinue the current nolasiban IVF program
and will explore potential repositioning of the product candidate."
ObsEva added a share listing in Switzerland last year, in addition
to trading on the Nasdaq in the United States starting in 2017. The
shares are down 36% this year.
(Reporting by John Miller; Editing by Michael Shields)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
